[1]
|
Wu, J.T., Leung, K. and Leung, G.M. (2020) Nowcasting and Forecasting the Potential Domestic and International Spread of the 2019-nCoV Outbreak Originating in Wuhan, China: A Modelling Study. The Lancet, 395, 689-697. https://doi.org/10.1016/S0140-6736(20)30260-9
|
[2]
|
Hui, D.S., Hui, D.S., Azhar, E.I., Madani, T.A., Ntoumi, F., et al. (2020) The Continuing 2019-nCoV Epidemic Threat of Novel Coronaviruses to Global Health—The Latest 2019 Novel Coronavirus Outbreak in Wuhan, China. International Journal of Infectious Diseases, 91, 264-266. https://doi.org/10.1016/j.ijid.2020.01.009
|
[3]
|
Coronaviridae Study Group of the International Committee on Taxonomy of Viruses (2020) The Species Severe Acute Respiratory Syndrome-Related Coronavirus: Classifying 2019-nCoV and Naming It SARS-CoV2. Nature Microbiology, 5, 536-544. https://doi.org/10.1038/s41564-020-0695-z
|
[4]
|
Li, W., Moore, M.J., Vasilieva, N., Sui, J., Wong, S.K., Berne, M.A., Somasundaran, M., Sullivan, J., Luzuriaga, K., Greenough, T., Choe, H. and Farzan, M. (2003) Angiotensin-Converting Enzyme 2 Is a Functional Receptor for the SARS Coronavirus. Nature, 426, 450-454. https://doi.org/10.1038/nature02145
|
[5]
|
Penninger, L., Grant, M. and Sung, J. (2021) The Role of Angiotensin Converting Enzyme 2 in Modulating Gut Microbiota, Intestinal Inflammation, and Coronavirus Infection. Gastroenterol, 160, 39-46. https://doi.org/10.1053/j.gastro.2020.07.067
|
[6]
|
Jothimani, D., Venugopal, R., Abedin, M.F. Kaliamoorthy, I. and Rela, M. (2020) COVID-19 and the Liver. Journal of Hepatology, 73, 1231. https://doi.org/10.1016/j.jhep.2020.06.006
|
[7]
|
Chai, X., Hu, L., Zhang, Y., Han, W., Lu, Z., Ke, A., Zhou, J., Shi, G., Fang, N., Fan, J., Cai, J., Fan, J. and Lan, F. (2020) Specific ACE2 Expression in Cholangiocytes May Cause Liver Damage after 2019-nCoV Infection.
|
[8]
|
Lagana, S.M., Kudose, S., Iuga, A., Lee, M.J., Fazlollahi, L., Remotti, H.E., Del Portillo, A., De Michele, S., de Gonzalez, A., Saqi, A., Khairallah, P., Chong, A.M., Park, H., Uhlemann, A., Lefkowitch, J.H. and Verna, E.C. (2020) Hepatic Pathology in Patients Dying of COVID-19: A Series of 40 Cases Including Clinical, Histologic, and Virologic Data. Modern Pathology, 33, 2147-2155. https://doi.org/10.1038/s41379-020-00649-x
|
[9]
|
Xu, L., Liu, J., Lu, M., Yang, D. and Zheng, X. (2020) Liver Injury during Highly Pathogenic Human Coronavirus Infections. Liver International, 40, 998-1004. https://doi.org/10.1111/liv.14435
|
[10]
|
Boettler, T., Newsome, P.N., Mondelli, M.U., Maticic, M., Cordero, E., Cornberg, M. and Berg, T. (2020) Care of Patients with Liver Disease during the COVID-19 Pandemic: EASL-ESCMID Position Paper. JHEP Reports, 2, Article ID: 100113. https://doi.org/10.1016/j.jhepr.2020.100113
|
[11]
|
Zhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z., Xiang, J., Wang, Y., Song, B., Gu, X., Guan, L., Wei, Y., Li, H., Wu, X., Xu, J., Tu, S., Zhang, Y., Chen, H. and Cao, B. (2020) Clinical Course and Risk Factors for Mortality of Adult in Patients with COVID-19 in Wuhan, China: A Retrospective Cohort Study. The Lancet, 395, 1054-1062. https://doi.org/10.1016/S0140-6736(20)30566-3
|
[12]
|
Wang, D., Hu, B., Hu, C., Zhu, F., Liu, X., Zhang, J., Wang, B., Xiang, H., Cheng, Z., Xiong, Y., Zhao, Y., Li, Y., Wang, X. and Peng, Z. (2020) Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. The Journal of the American Medical Association, 23, 1061-1069. https://doi.org/10.1001/jama.2020.1585
|
[13]
|
Xu, X.W., Wu, X.X., Jiang, X.G., Xu, K.J., Ying, L.J., Ma, C.L., et al. (2020) Clinical Findings in a Group of Patients Infected with the 2019 Novel Coronavirus (SARS-Cov-2) Outside of Wuhan, China: Retrospective Case Series. British Medical Journal, 368, m606. https://doi.org/10.1136/bmj.m606
|
[14]
|
Xiang, F., Sun, J., Chen, P., Han, P., Zheng, H., Cai, S. and Kirk, G. (2021) Early Elevation of FIB-4 Liver Fibrosis Score Is Associated with Adverse Outcomes among Patients with COVID-19. Clinical Infectious Diseases, 73, e594-e601. https://doi.org/10.1093/cid/ciaa1710
|
[15]
|
Cao, X. (2020) COVID-19: Immunopathology and Its Implications for Therapy. Nature Reviews Immunology, 20, 269-270. https://doi.org/10.1038/s41577-020-0308-3
|
[16]
|
Chai, X., Hu, L., Zhang, Y., Han, W., Lu, Z., Ke, A., Zhou, J., Shi, G., Fang, N., Fan, J., Cai, J., Fan, J. and Lan, F. (2020) Specific ACE2 Expression in Cholangiocytes may Cause Liver Damage after 2019-nCoV Infection. Bio-Rxiv. https://doi.org/10.1101/2020.02.03.931766
|
[17]
|
Zhang, C., Shi, L. and Wang, F.S. (2020) Liver Injury in COVID-19: Management and Challenges. The Lancet Gastroenterology and Hepatology, 5, 428-430. https://doi.org/10.1016/S2468-1253(20)30057-1
|
[18]
|
LactMed (2006) Remdesivir. Drugs and Lactation Database. National Library of Medicine (US), Bethesda.
|
[19]
|
Beigel, J.H., Tomashek, K.M., Dodd, L.E., Mehta, A.K., Zingman, B.S., Kalil, A.C., Hohmann, E., Chu, H., Luetkemeyer, A., Kline, S., de Castilla, D., Finberg, R., Dierberg, K., Tapson, V., Hsieh, L., Patterson, T., Paredes, R., Sweeney, D., Short, W., Touloumi, G., Lye, D., Ohmagari, N., Oh, M., Ruiz-Palacios, G., Benfield, T., Fatkenheuer, G., Kortepeter, M., Atmar, R., Creech, C., Lundgren, J., Babiker, A., Pett, S., Neaton, J., Burgess, T., Bonnett, T., Green, M., Makowski, M., Osinusi, A., Nayak, S. and Lane, H. (2020) Remdesivir for the Treatment of Covid-19 Preliminary Report. The New England Journal of Medicine, 383, 1813-1826. https://doi.org/10.1056/NEJMoa2007764
|
[20]
|
Wang, Y., Zhang, D., Du, G., Du, R., Zhao, J., Jin, Y., Fu, S., Gao, L., Cheng, Z., Lu, Q., Hu, Y., Luo, G., Wang, K., Lu, Y., Li, H., Wang, S., Ruan, S., Yang, C., Mei, C., Wang, Y., Ding, D., Wu, F., Tang, X., Ye, X., Ye, Y., Liu, B., Yang, J., Yin, W., Wang, A., Fan, G., Zhou, F., Liu, Z., Gu, X., Xu, J., Shang, L., Zhang, Y., Cao, L., Guo, T., Wan, Y., Qin, H., Jaki, T., Hayden, F., Horby, P., Cao, B. and Wang, C. (2020) Remdesivir in Adults with Severe COVID-19: A Randomised, Double-Blind, Placebo-Controlled, Multicentre Trial. The Lancet, 395, 1569-1578. https://doi.org/10.1016/S0140-6736(20)31022-9
|
[21]
|
Maini, R.N., Taylor, P.C., Szechinski, J., Pavelka, K., Broll, J., Balint, G., Emery, P., Raemen, F., Petersen, J., Smolen, J., Thomson, D. and Kishimoto, T. (2006) Double Blind Randomized Controlled Clinical Trial of the Interleukin-6 Receptor Antagonist, Tocilizumab, in European Patients with Rheumatoid Arthritis Who Had an Incomplete Response to Methotrexate. Arthritis & Rheumatology, 54, 2817-2829. https://doi.org/10.1002/art.22033
|
[22]
|
Chen, L.F., Mo, Y.Q., Jing, J., Ma, J.D., Zheng, D.H. and Dai, L. (2017) Short-Course Tocilizumab Increases Risk of Hepatitis B Virus Reactivation in Patients with Rheumatoid Arthritis: A Prospective Clinical Observation. International Journal of Rheumatic Diseases, 20, 859-869. https://doi.org/10.1111/1756-185X.13010
|
[23]
|
Brenner, E.J., Ungaro, R.C., Gearry, R.B., Kaplan, G.G., Kissous-Hunt, M., Lewis, J.D., Ng, S.C., Rahier, J., Reinisch, W., Ruemmele, F.M., Steinwurz, F., Underwood, F.E., Zhang, X., Colombel, J. and Kappelman, M.D. (2020) Corticosteroids, But Not TNF Antagonists, Are Associated with Adverse COVID-19 Outcomes in Patients with Inflammatory Bowel Diseases: Results from an International Registry. Gastroenterology, 159, 481-491. https://doi.org/10.1053/j.gastro.2020.05.032
|
[24]
|
Gianfrancesco, M., Hyrich, K.L., Al-Adely, S., Carmona, L., Danila, M.I., Gossec, L., Izadi, Z., Jacobsohn, L., Katz, P., Lawson-Tovey, S., Mateus, E., Rush, S., Schmajuk, G., Simard, J., Strangfeld, A., Trupin, L., Wysham, K., Bhana, S., Costello, W., Grainger, R., Hausmann, J., Liew, J., Sirotich, E., Sufka, P., Wallace, Z., Yazdany, J., Machado, P. and Robinson, P. (2020) Characteristics Associated with Hospitalisation for COVID-19 in People with Rheumatic Disease: Data from the COVID-19 Global Rheumatology Alliance Physician-Reported Registry. Annals of the Rheumatic Diseases, 79, 859-866. https://doi.org/10.1136/annrheumdis-2020-217871
|
[25]
|
Boettler, T., Marjot, T., Newsome, P.N., Mondelli, M.U., Maticic, M., Cordero, E., Jalan, R., Moreau, R., Cornberg, M. and Berg, T. (2020) Impact of COVID-19 on the Care of Patients with Liver Disease: EASL-ESCMID Position Paper after 6 Months of the Pandemic. JHEP Reports, 2, Article ID: 100169. https://doi.org/10.1016/j.jhepr.2020.100169
|
[26]
|
Loffredo, L., Pastori, D., Farcomeni, A. and Violi, F. (2017) Effects of Anticoagulants in Patients with Cirrhosis and Portal Vein Thrombosis: A Systematic Review and Meta-Analysis. Gastroenterology, 153, 480-487. https://doi.org/10.1053/j.gastro.2017.04.042
|
[27]
|
Turco, L., de Raucourt, E., Valla, D.C. and Villa, E. (2019) Anticoagulation in the Cirrhotic Patient. JHEP Reports, 1, 227-239. https://doi.org/10.1016/j.jhepr.2019.02.006
|
[28]
|
Villa, E., Cammà, C., Marietta, M., Luongo, M., Critelli, R., Colopi, S., Tata, C., Zecchini, R., Gitto, S., Petta, S., Lei, B., Bernabucci, V., Vukotic, R., De Maria, N., Schepis, F., Karampatou, A., Caporali, C., Simoni, L., Del Buono, M., Zambotto, B., Turola, E., Fornaciari, G., Schianchi, S., Ferrari, A. and Valla, D. (2012) Enoxaparin Prevents Portal Vein Thrombosis and Liver Decompensation in Patients with Advanced Cirrhosis. Gastroenterology, 143, 1253-1260. https://doi.org/10.1053/j.gastro.2012.07.018
|
[29]
|
Iavarone, M., D’Ambrosio, R., Soria, A., Triolo, M., Pugliese, N., Del Poggio, P., Perricone, G., Massironi, S., Spinetti, A., Buscarini, E., Viganò, M., Carriero, C., Fagiuoli, S., Aghemo, A., Belli, L., Lucà, M., Pedaci, M., Rimondi, A., Rumi, M., Invernizzi, P., Bonfanti, P. and Lampertico, P. (2020) High Rates of 30-Day Mortality in Patients with Cirrhosis and COVID-19. Journal of Hepatology, 73, 1534. https://doi.org/10.1016/j.jhep.2020.08.001
|
[30]
|
Team CC-R (2020) Preliminary Estimates of the Prevalence of Selected Underlying Health Conditions among Patients with Coronavirus Disease 2019—United States, February 12-March 28, 2020. Morbidity and Mortality Weekly Report, 69, 382-386. https://doi.org/10.15585/mmwr.mm6913e2
|
[31]
|
Williamson, E., Walker, A.J., Bhaskaran, K.J., Bacon, S., Bates, C., Morton, C.E., Curtis, H., Mehrkar, A., Evans, D., Inglesby, P., Cockburn, J., McDonald, H., MacKenna, B., Tomlinson, L., Douglas, I., Rentsch, C., Mathur, R., Wong, A., Grieve, R., Harrison, D., Forbes, H., Schultze, A., Croker, R., Parry, J., Hester, F., Harper, S., Perera, R., Evans, S., Smeeth, L. and Goldacre, B. (2020) Open SAFELY: Factors Associated with COVID-19 Death in 17 Million Patients. Nature, 584, 430-436. https://doi.org/10.1038/s41586-020-2521-4
|
[32]
|
Ji, D., Zhang, D., Yang, T., Mu, J., Zhao, P., Xu, J., Li, C., Cheng, G., Wang, Y., Chen, Z., Qin, E. and Lau, G. (2020) Effect of COVID-19 on Patients with Compensated Chronic Liver Diseases. Hepatology International, 14, 701-710. https://doi.org/10.1007/s12072-020-10058-6
|
[33]
|
Singh, S. and Khan, A. (2020) Clinical Characteristics and Outcomes of Coronavirus Disease 2019 among Patients with Preexisting Liver Disease in the United States: A Multicenter Research Network Study. Gastroenterology, 159, 768-771. https://doi.org/10.1053/j.gastro.2020.04.064
|
[34]
|
Marjot, T., Moon, A., Cook, J., Abd-Elsalam, S., Aloman, C., Armstrong, M., Pose, E., Brenner, E.J., Cargill, T., Catana, M., Dhanasekaran, R., Eshraghian, A., García-Juárez, I., Gill, U., Jones, P., Kennedy, J., Marshall, A., Matthews, C., Mells, G., Mercer, C., Perumalswami, P., Avitabile, B., Qi, X., Su, F., Ufere, N., Wong, Y., Zheng, M., Barnes, E., Barritt, A. and Webb, G. (2021) Outcomes Following SARS-CoV-2 Infection in Patients with Chronic Liver Disease: An International Registry Study. Journal of Hepatology, 74, 567-577.
|
[35]
|
Bajaj, J.S., Garcia-Tsao, G., Biggins, S., Kamath, P.S., Wong, F., McGeorge, S., Shaw, A., Pearson, M., Chew, M., Fagan, A., Rodriguez, R., Worthington, J., Olofson, A., Weir, V., Trisolini, C., Dwyer, S. and Reddy, K. (2021) Comparison of Mortality Risk in Patients with Cirrhosis and COVID-19 Compared with Patients with Cirrhosis Alone and COVID-19 Alone: Multicentre Matched Cohort. Gut, 70, 531-536. https://doi.org/10.1136/gutjnl-2020-322118
|
[36]
|
Schmidt, M.L., Barritt, A.S., Orman, E. and Hayashi, P.H. (2015) Decreasing Mortality among Patients Hospitalized with Cirrhosis in the United States from 2002 through 2010. Gastroenterology, 148, 967-977. https://doi.org/10.1053/j.gastro.2015.01.032
|
[37]
|
Kanwal, F., Tansel, A., Kramer, J.R., Feng, H., Asch, S.M. and El-Serag, H.B. (2017) Trends in 30-Day and 1-Year Mortality among Patients Hospitalized with Cirrhosis from 2004 to 2013. American Journal of Gastroenterology, 112, 1287-1297. https://doi.org/10.1038/ajg.2017.175
|
[38]
|
Kim, D., Adeniji, N., Latt, N., Kumar, S., Bloom, P., Aby, E., Perumalswami, P., Roytman, M., Li, M., Vogel, A., Catana, A., Wegermann, K., Carr, R., Aloman, C., Chen, V., Rabiee, A., Sadowski, B., Nguyen, V., Dunn, W., Chavin, K., Zhou, K., Lizaola-Mayo, B., Moghe, A., Debes, J., Lee, T., Branch, A., Viveiros, K., Chan, W., Chascsa, D., Kwo, P. and Dhanasekaran, R. (2020) Predictors of Outcomes of COVID-19 in Patients with Chronic Liver Disease: US Multi-Center Study. Clinical Gastroenterology and Hepatology, 19, 1469-1479.e19. https://doi.org/10.1016/j.cgh.2020.09.027
|
[39]
|
Tapper, E.B., Sengupta, N. and Bonder, A. (2015) The Incidence and Outcomes of Ischemic Hepatitis: A Systematic Review with Meta-Analysis. The American Journal of Medicine, 128, 1314-1321. https://doi.org/10.1016/j.amjmed.2015.07.033
|
[40]
|
WHO (2016) Global Health Sector Strategy on Viral Hepatitis 2016-2021: Towards Ending Viral Hepatitis. World Health Organization, Geneva.
|
[41]
|
Blach, S., Kondili, L., Aghemo, A., Cai, Z., Dugan, E., Estes, C., Gamkrelidze, I., Ma, S., Pawlotsky, J., Razavi-Shearer, D., Razavi, H., Waked, I., Zeuzem, S. and Craxi, A. (2021) Impact of COVID-19 on Global HCV Elimination Efforts. Journal of Hepatology, 74, 31-36. https://doi.org/10.1016/j.jhep.2020.07.042
|
[42]
|
Lampertico, P., Agarwal, K., Berg, T., Buti, M., Janssen, H.L.A., Papatheodoridis, G. and Zoulim, F. (2017) EASL 2017 Clinical Practice Guidelines on the Management of Hepatitis B Virus Infection. Journal of Hepatology, 67, 370-398. https://doi.org/10.1016/j.jhep.2017.03.021
|
[43]
|
Pawlotsky, J.-M., Negro, F., Aghemo, A., Berenguer, M., Dalgard, O., Dusheiko, G., Marra, F., Puoti, M. and Wedemeyer, H. (2018) EASL Recommendations on Treatment of Hepatitis C 2018. Journal of Hepatology, 69, 461-511. https://doi.org/10.1016/j.jhep.2018.03.026
|
[44]
|
Moon, A.M., Webb, G.J., Aloman, C., Armstrong, M.J., Cargill, T., Dhanasekaran, R., Genescà, J., Gill, U., James, T., Jones, P., Marshall, A., Mells, G., Perumalswami, P., Qi, X., Su, F., Ufere, N., Barnes, E., Barritt, A. and Marjot, T. (2020) High Mortality Rates for SARS-CoV-2 Infection in Patients with Preexisting Chronic Liver Disease and Cirrhosis: Preliminary Results from an International Registry. Journal of Hepatology, 73, 705-708. https://doi.org/10.1016/j.jhep.2020.05.013
|